BTB Therapeutics, Inc.
Escondido, US · Founded 2024 · Delaware corporation · 1 known investors
Find your way into BTB Therapeutics, Inc.
242 people in our graph share verified history with the BTB Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Scott Maxwellunlockedknows Takashi Kiyoizumi · together at MIT Sloan School of Management (overlapped)
knows the team · via MIT Sloan School of Management
knows the team · via NuFund Venture Group
×9knows the team · via Keio University
BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.
Founders & leadership
BTB Therapeutics, Inc. was founded in 2024 by Masatoshi Hagiwara.
MH
Masatoshi HagiwaraChief Scientific Officer, Director of the Board (founder of BTB Therapeutics Co., Ltd.)
TK
Takashi KiyoizumiinChief Executive OfficerTakashi Kiyoizumi holds an MD, PhD, and MBA from MIT Sloan. He has served as CEO of multiple pharmaceutical startups and held board positions in life science companies, with experience in capital raising and strategic licensing agreements.
KW
Kenneth W. LockeChief Development Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements$12.2M disclosed across 2 rounds · 2025
▶$8.9MraisedAug 2026 · 4 investors · PharmaceuticalsRule 506(b)
▶$8.9MraisedAug 2026 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Takashi KiyoizumiExecutive Officer, Director
- Nobuhiro YagiDirector
- Masatoshi HagiwaraDirector
- David SnyderDirector
- Sidney YeeDirector
- Offering amount
- $10.4M
- Amount sold
- $8.9M
- Proceeds to insiders
- $250K
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$3.3MraisedFeb 2025 · 10 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedFeb 2025 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Takashi KiyoizumiExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Northwest Biotherapeutics6 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
Crossbow Therapeutics5 shared keywordsCrossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
Shinobi Therapeutics Inc.4 shared keywordsShinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.
Krystalbio4 shared keywordsKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
C4 Therapeutics3 shared keywordsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Bolt Biotherapeutics3 shared keywordsBolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer. The company focuses on cancer immunotherapeutics and myeloid biology to address unmet patient needs.
Obsidiantx3 shared keywordsObsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
Companies competing with BTB Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does BTB Therapeutics, Inc. do?
- BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.
- Who founded BTB Therapeutics, Inc.?
- BTB Therapeutics, Inc. was founded by Masatoshi Hagiwara in 2024.
- Who are BTB Therapeutics, Inc.'s investors?
- BTB Therapeutics, Inc.'s investors include Kyoto University Innovation Capital.
- How much funding has BTB Therapeutics, Inc. raised?
- BTB Therapeutics, Inc. has disclosed $12.2M raised across 2 rounds.
- Where is BTB Therapeutics, Inc. headquartered?
- BTB Therapeutics, Inc. is headquartered in Escondido, US.